Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim N Chi

Showing results (141-150 of 234) with videos related to

Pageof 24
Sort By:
Investigational New Drugs|May 3, 2014
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patientsAnna Spreafico, Kim N Chi, Srikala S Sridhar, et al.
Cancer|March 10, 2021
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancerDaniel H Kwon, Jonathan Chou, Steven M Yip, et al.
NPJ Precision Oncology|March 14, 2023
A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomesElie J Ritch, Cameron Herberts, Evan W Warner, et al.
The New England Journal of Medicine|September 21, 2020
Survival with Olaparib in Metastatic Castration-Resistant Prostate CancerMaha Hussain, Joaquin Mateo, Karim Fizazi, et al.
The New England Journal of Medicine|April 29, 2020
Olaparib for Metastatic Castration-Resistant Prostate CancerJohann de Bono, Joaquin Mateo, Karim Fizazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2019
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerElie Ritch, Simon Y F Fu, Cameron Herberts, et al.
European Urology|January 7, 2024
Safety Analyses of the Phase 3 VISION Trial of [<sup>177</sup>Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate CancerKim N Chi, Andrew J Armstrong, Bernd J Krause, et al.
European Urology|January 15, 2019
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate CancerGillian Vandekerkhove, Werner J Struss, Matti Annala, et al.
Molecular Oncology|January 27, 2016
Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progressionFrancesco Crea, Luca Quagliata, Agnieszka Michael, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate CancerArun A Azad, Stanislav V Volik, Alexander W Wyatt, et al.
Pageof 24

Showing results (141-150 of 234) with videos related to

Sort By:
Pageof 24
Investigational New Drugs|May 3, 2014
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patientsAnna Spreafico, Kim N Chi, Srikala S Sridhar, et al.
Cancer|March 10, 2021
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancerDaniel H Kwon, Jonathan Chou, Steven M Yip, et al.
NPJ Precision Oncology|March 14, 2023
A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomesElie J Ritch, Cameron Herberts, Evan W Warner, et al.
The New England Journal of Medicine|September 21, 2020
Survival with Olaparib in Metastatic Castration-Resistant Prostate CancerMaha Hussain, Joaquin Mateo, Karim Fizazi, et al.
The New England Journal of Medicine|April 29, 2020
Olaparib for Metastatic Castration-Resistant Prostate CancerJohann de Bono, Joaquin Mateo, Karim Fizazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2019
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerElie Ritch, Simon Y F Fu, Cameron Herberts, et al.
European Urology|January 7, 2024
Safety Analyses of the Phase 3 VISION Trial of [<sup>177</sup>Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate CancerKim N Chi, Andrew J Armstrong, Bernd J Krause, et al.
European Urology|January 15, 2019
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate CancerGillian Vandekerkhove, Werner J Struss, Matti Annala, et al.
Molecular Oncology|January 27, 2016
Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progressionFrancesco Crea, Luca Quagliata, Agnieszka Michael, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate CancerArun A Azad, Stanislav V Volik, Alexander W Wyatt, et al.
Pageof 24